Search research articles
Contact Us
Filters
Showing results (81-90 of 86) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 86 results.
Nature Communications
|
March 28, 2020
A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma
Li Ren Kong, Nur Afiqah Binte Mohamed Salleh, Richard Weijie Ong, et al.
Cancer Discovery
|
September 22, 2020
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i>-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers
Javier Pascual, Joline S J Lim, Iain R Macpherson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 1, 2022
Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer
Joline S J Lim, Andrea L A Wong, Samuel G W Ow, et al.
Nature Communications
|
November 12, 2025
A non-canonical lymphoblast in refractory childhood T-cell leukaemia
Bram S J Lim, Holly J Whitfield, Mi K Trinh, et al.
Annals of Surgical Oncology
|
September 7, 2022
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases
Daryl K A Chia, Raghav Sundar, Guowei Kim, et al.
Cancer Discovery
|
June 14, 2020
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non-<i>BRCA1/2</i>-Mutant Cancers
Timothy A Yap, Rebecca Kristeleit, Vasiliki Michalarea, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 86) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 86 results.
Nature Communications
|
March 28, 2020
A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma
Li Ren Kong, Nur Afiqah Binte Mohamed Salleh, Richard Weijie Ong, et al.
Cancer Discovery
|
September 22, 2020
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i>-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers
Javier Pascual, Joline S J Lim, Iain R Macpherson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 1, 2022
Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer
Joline S J Lim, Andrea L A Wong, Samuel G W Ow, et al.
Nature Communications
|
November 12, 2025
A non-canonical lymphoblast in refractory childhood T-cell leukaemia
Bram S J Lim, Holly J Whitfield, Mi K Trinh, et al.
Annals of Surgical Oncology
|
September 7, 2022
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases
Daryl K A Chia, Raghav Sundar, Guowei Kim, et al.
Cancer Discovery
|
June 14, 2020
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non-<i>BRCA1/2</i>-Mutant Cancers
Timothy A Yap, Rebecca Kristeleit, Vasiliki Michalarea, et al.
Page
of 9